Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R‐ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were...

Full description

Saved in:
Bibliographic Details
Published inCancer medicine (Malden, MA) Vol. 7; no. 8; pp. 4132 - 4145
Main Authors Radocha, Jakub, Maisnar, Vladimír, Pour, Luděk, Špička, Ivan, Minařík, Jiři, Szeligová, Lenka, Pavlíček, Petr, Jungová, Alexandra, Krejčí, Marta, Pika, Tomáš, Straub, Jan, Brožová, Lucie, Stejskal, Lukáš, Heindorfer, Adriana, Jindra, Pavel, Kessler, Petr, Mikula, Peter, Sýkora, Michal, Wróbel, Marek, Jarkovský, Jiří, Hájek, Roman
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.08.2018
John Wiley and Sons Inc
Subjects
Adult
Aged
Aged, 80 and over
Cancer Prevention
Clinical medicine
Cytogenetics
Czech Myeloma Group Registry
Czech Republic - epidemiology
Diagnosis
Female
Humans
Male
Middle Aged
monoclonal gammopathies
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - epidemiology
Neoplasm Staging
Original Research
overall survival
Paraproteinemias - diagnosis
Paraproteinemias - epidemiology
Patients
Practice Patterns, Physicians
real‐world
Registries
Retrospective Studies
Risk Assessment
Risk Factors
risk stratification
Survival
Survival Analysis
Czech Republic
overall survival
real-world
multiple myeloma
risk stratification
Czech Myeloma Group Registry
monoclonal gammopathies
Online AccessGet full text

Cover

Abstract This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R‐ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were included if they had symptomatic MM, complete data allowing R‐ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival (OS) in included patients (n = 550) was 47.7 (95% CI: 39.5‐55.9) and 46.2 (95% CI: 38.9‐53.5) months from diagnosis and initiation of first‐line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI: 30.5‐40.3) vs 58.3 (95% CI: 53.8‐62.9) months in high‐risk vs other patients (IMWG; P = .001) and 34.1 (95% CI: 30.2‐38.0) vs 47.2 (95% CI: 43.4‐51.0) months in Stage III vs Stage II patients (R‐ISS; P < .001). In conclusion, IMWG and R‐ISS risk stratification indices are applicable to patients with MM in a real‐world setting. We have successfully validated R‐ISS myeloma prognostic score on real‐life unselected population. The system can be broadly applicable outside clinical trials.
AbstractList This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R‐ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were included if they had symptomatic MM, complete data allowing R‐ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival (OS) in included patients (n = 550) was 47.7 (95% CI: 39.5‐55.9) and 46.2 (95% CI: 38.9‐53.5) months from diagnosis and initiation of first‐line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI: 30.5‐40.3) vs 58.3 (95% CI: 53.8‐62.9) months in high‐risk vs other patients (IMWG; P = .001) and 34.1 (95% CI: 30.2‐38.0) vs 47.2 (95% CI: 43.4‐51.0) months in Stage III vs Stage II patients (R‐ISS; P < .001). In conclusion, IMWG and R‐ISS risk stratification indices are applicable to patients with MM in a real‐world setting.
Abstract This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group ( IMWG ) and revised International Staging System (R‐ ISS ) indices for risk stratification in patients with multiple myeloma ( MM ) in clinical practice. Patients were included if they had symptomatic MM , complete data allowing R‐ ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival ( OS ) in included patients (n = 550) was 47.7 (95% CI : 39.5‐55.9) and 46.2 (95% CI : 38.9‐53.5) months from diagnosis and initiation of first‐line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI : 30.5‐40.3) vs 58.3 (95% CI : 53.8‐62.9) months in high‐risk vs other patients ( IMWG ; P  = .001) and 34.1 (95% CI : 30.2‐38.0) vs 47.2 (95% CI : 43.4‐51.0) months in Stage III vs Stage II patients (R‐ ISS ; P  < .001). In conclusion, IMWG and R‐ ISS risk stratification indices are applicable to patients with MM in a real‐world setting.
This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R‐ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were included if they had symptomatic MM, complete data allowing R‐ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival (OS) in included patients (n = 550) was 47.7 (95% CI: 39.5‐55.9) and 46.2 (95% CI: 38.9‐53.5) months from diagnosis and initiation of first‐line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI: 30.5‐40.3) vs 58.3 (95% CI: 53.8‐62.9) months in high‐risk vs other patients (IMWG; P = .001) and 34.1 (95% CI: 30.2‐38.0) vs 47.2 (95% CI: 43.4‐51.0) months in Stage III vs Stage II patients (R‐ISS; P < .001). In conclusion, IMWG and R‐ISS risk stratification indices are applicable to patients with MM in a real‐world setting. We have successfully validated R‐ISS myeloma prognostic score on real‐life unselected population. The system can be broadly applicable outside clinical trials.
This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group ( IMWG ) and revised International Staging System (R‐ ISS ) indices for risk stratification in patients with multiple myeloma ( MM ) in clinical practice. Patients were included if they had symptomatic MM , complete data allowing R‐ ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival ( OS ) in included patients (n = 550) was 47.7 (95% CI : 39.5‐55.9) and 46.2 (95% CI : 38.9‐53.5) months from diagnosis and initiation of first‐line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI : 30.5‐40.3) vs 58.3 (95% CI : 53.8‐62.9) months in high‐risk vs other patients ( IMWG ; P  = .001) and 34.1 (95% CI : 30.2‐38.0) vs 47.2 (95% CI : 43.4‐51.0) months in Stage III vs Stage II patients (R‐ ISS ; P  < .001). In conclusion, IMWG and R‐ ISS risk stratification indices are applicable to patients with MM in a real‐world setting.
This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R-ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were included if they had symptomatic MM, complete data allowing R-ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival (OS) in included patients (n = 550) was 47.7 (95% CI: 39.5-55.9) and 46.2 (95% CI: 38.9-53.5) months from diagnosis and initiation of first-line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI: 30.5-40.3) vs 58.3 (95% CI: 53.8-62.9) months in high-risk vs other patients (IMWG; P = .001) and 34.1 (95% CI: 30.2-38.0) vs 47.2 (95% CI: 43.4-51.0) months in Stage III vs Stage II patients (R-ISS; P < .001). In conclusion, IMWG and R-ISS risk stratification indices are applicable to patients with MM in a real-world setting.
Author Heindorfer, Adriana
Jarkovský, Jiří
Jungová, Alexandra
Brožová, Lucie
Maisnar, Vladimír
Pika, Tomáš
Jindra, Pavel
Kessler, Petr
Straub, Jan
Minařík, Jiři
Hájek, Roman
Szeligová, Lenka
Krejčí, Marta
Wróbel, Marek
Pour, Luděk
Stejskal, Lukáš
Sýkora, Michal
Špička, Ivan
Radocha, Jakub
Pavlíček, Petr
Mikula, Peter
AuthorAffiliation 1 4th Department of Medicine – Haematology Faculty of Medicine Charles University Hospital Hradec Králové Czech Republic
3 1st Medical Department – Clinical Department of Haematology of the First Faculty of Medicine General Teaching Hospital Charles University Prague Czech Republic
13 Department of Clinical Hematology Hospital Ceske Budejovice Ceske Budejovice Czech Republic
2 Department of Internal Medicine, Hematology and Oncology University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic
9 Department of Hematology Hospital Opava Opava Czech Republic
14 Department of Hematology Hospital Novy Jicin Novy Jicin Czech Republic
10 Department of Hematology Hospital Liberec Liberec Czech Republic
5 Department of Haemato‐Oncology Faculty of Medicine University Hospital Ostrava University of Ostrava Ostrava Czech Republic
11 Department of Hematology and Transfusion Medicine Hospital Pelhrimov Pelhrimov Czech Republic
6 Department of Internal Medicine and Hematology University
AuthorAffiliation_xml – name: 12 Department of Clinical Haematology Hospital in Havirov Havirov Czech Republic
– name: 6 Department of Internal Medicine and Hematology University Hospital Kralovske Vinohrady Prague Czech Republic
– name: 13 Department of Clinical Hematology Hospital Ceske Budejovice Ceske Budejovice Czech Republic
– name: 11 Department of Hematology and Transfusion Medicine Hospital Pelhrimov Pelhrimov Czech Republic
– name: 2 Department of Internal Medicine, Hematology and Oncology University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic
– name: 7 Hematology and Oncology Department Charles University Hospital Pilsen Czech Republic
– name: 10 Department of Hematology Hospital Liberec Liberec Czech Republic
– name: 1 4th Department of Medicine – Haematology Faculty of Medicine Charles University Hospital Hradec Králové Czech Republic
– name: 9 Department of Hematology Hospital Opava Opava Czech Republic
– name: 5 Department of Haemato‐Oncology Faculty of Medicine University Hospital Ostrava University of Ostrava Ostrava Czech Republic
– name: 14 Department of Hematology Hospital Novy Jicin Novy Jicin Czech Republic
– name: 3 1st Medical Department – Clinical Department of Haematology of the First Faculty of Medicine General Teaching Hospital Charles University Prague Czech Republic
– name: 4 Department of Hemato‐Oncology Faculty of Medicine and Dentistry University Hospital Olomouc Palacky University Olomouc Czech Republic
– name: 8 Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
Author_xml – sequence: 1
  givenname: Jakub
  orcidid: 0000-0002-5384-8238
  surname: Radocha
  fullname: Radocha, Jakub
  email: jakub.radocha@centrum.cz
  organization: Charles University Hospital
– sequence: 2
  givenname: Vladimír
  surname: Maisnar
  fullname: Maisnar, Vladimír
  organization: Charles University Hospital
– sequence: 3
  givenname: Luděk
  surname: Pour
  fullname: Pour, Luděk
  organization: Faculty of Medicine Masaryk University
– sequence: 4
  givenname: Ivan
  surname: Špička
  fullname: Špička, Ivan
  organization: General Teaching Hospital Charles University
– sequence: 5
  givenname: Jiři
  surname: Minařík
  fullname: Minařík, Jiři
  organization: Palacky University
– sequence: 6
  givenname: Lenka
  surname: Szeligová
  fullname: Szeligová, Lenka
  organization: University of Ostrava
– sequence: 7
  givenname: Petr
  surname: Pavlíček
  fullname: Pavlíček, Petr
  organization: University Hospital Kralovske Vinohrady
– sequence: 8
  givenname: Alexandra
  surname: Jungová
  fullname: Jungová, Alexandra
  organization: Charles University Hospital
– sequence: 9
  givenname: Marta
  surname: Krejčí
  fullname: Krejčí, Marta
  organization: Faculty of Medicine Masaryk University
– sequence: 10
  givenname: Tomáš
  surname: Pika
  fullname: Pika, Tomáš
  organization: Palacky University
– sequence: 11
  givenname: Jan
  surname: Straub
  fullname: Straub, Jan
  organization: General Teaching Hospital Charles University
– sequence: 12
  givenname: Lucie
  surname: Brožová
  fullname: Brožová, Lucie
  organization: Masaryk University
– sequence: 13
  givenname: Lukáš
  surname: Stejskal
  fullname: Stejskal, Lukáš
  organization: Hospital Opava
– sequence: 14
  givenname: Adriana
  surname: Heindorfer
  fullname: Heindorfer, Adriana
  organization: Hospital Liberec
– sequence: 15
  givenname: Pavel
  surname: Jindra
  fullname: Jindra, Pavel
  organization: Charles University Hospital
– sequence: 16
  givenname: Petr
  surname: Kessler
  fullname: Kessler, Petr
  organization: Hospital Pelhrimov
– sequence: 17
  givenname: Peter
  surname: Mikula
  fullname: Mikula, Peter
  organization: Hospital in Havirov
– sequence: 18
  givenname: Michal
  surname: Sýkora
  fullname: Sýkora, Michal
  organization: Hospital Ceske Budejovice
– sequence: 19
  givenname: Marek
  surname: Wróbel
  fullname: Wróbel, Marek
  organization: Hospital Novy Jicin
– sequence: 20
  givenname: Jiří
  surname: Jarkovský
  fullname: Jarkovský, Jiří
  organization: Masaryk University
– sequence: 21
  givenname: Roman
  surname: Hájek
  fullname: Hájek, Roman
  organization: University of Ostrava
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29931775$$D View this record in MEDLINE/PubMed
BookMark eNp1ks1u1DAQgC1UREvpgRdAlrjQw7Z24jgJB6TVqixIXSEh4Gp5nXHXxT-pnYDCI_GUOOxSFSR8saX5_M2MZp6iIx88IPSckgtKSHGppGMXlBfkETopCKsWNS_Z0YP3MTpL6ZbkU5OC1_QJOi7atqR1XZ2gn1-kNZ0cTPA4aOxGO5jeAnYT2OAkjiZ9xWmImdBG7TnjO6Mg5RvHMA7GA1bW-By2uI9SDTn6Gi-9tFMyadbmBBLrGBwedoBXP0Dt8OaQYZ0dPf4INyanmWZ6E3xQNuT_eC2dC70cdgbSM_RYS5vg7HCfos9vrz6t3i2uP6zfr5bXC8VYSRYdp2qrtxVnIIkmqmulVATotim3TGrZtayFQmolQbVKUV6XmhHdVUxxrXRbnqI3e28_bh10Cnxu34o-GifjJII04u-INztxE74JTpqW8iYLXh0EMdyNkAbhTFJgrfQQxiQKUjVVHl1TZPTlP-htGGPufKaamhcFqetMne8pFUNKEfR9MZSIeQnEvARiXoLMvnhY_T35Z-QZuNwD342F6f8msVpu2G_lL8wGwzE
CitedBy_id crossref_primary_10_1007_s00277_024_05642_x
crossref_primary_10_1007_s00277_020_04162_8
crossref_primary_10_3389_fmed_2021_612696
crossref_primary_10_1007_s12185_022_03332_w
Cites_doi 10.14735/amko20172S43
10.1186/s13045-017-0492-1
10.1016/j.clml.2016.06.001
10.1016/j.euf.2016.09.008
10.1056/NEJM199607113350204
10.1182/blood.V126.23.4514.4514
10.1038/leu.2013.247
10.1200/JOP.2015.004929
10.1038/leu.2012.282
10.1200/JCO.2015.61.2267
10.3324/haematol.2010.023697
10.1200/JCO.2005.04.242
10.6004/jnccn.2010.0114
10.1016/j.mayocp.2013.01.019
10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
10.1038/nrclinonc.2016.122
10.1200/JCO.2012.46.2598
10.1200/JCO.2013.53.0329
10.1158/1078-0432.CCR-14-2576
10.1097/MD.0000000000003521
10.1002/ajh.24796
10.1080/14728222.2016.1266339
10.3324/haematol.2016.145078
10.1111/j.1600-0609.2010.01466.x
10.1002/ajh.24533
10.1016/j.clml.2011.07.001
ContentType Journal Article
Copyright 2018 The Authors. published by John Wiley & Sons Ltd.
2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2018 The Authors. published by John Wiley & Sons Ltd.
– notice: 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
– notice: 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7X7
7XB
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M7P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1002/cam4.1620
DatabaseName Wiley-Blackwell Open Access Titles(OpenAccess)
Wiley Online Library Open Access
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
PHMC-Proquest健康医学期刊库
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
Biological Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
CrossRef


MEDLINE
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley-Blackwell Open Access Titles(OpenAccess)
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate RADOCHA et al
EISSN 2045-7634
EndPage 4145
ExternalDocumentID 10_1002_cam4_1620
29931775
CAM41620
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Czech Republic
GeographicLocations_xml – name: Czech Republic
GrantInformation_xml – fundername: Takeda Pharmaceutical Company
GroupedDBID 0R~
1OC
24P
31~
53G
5VS
7X7
8-0
8-1
8FE
8FH
8FI
8FJ
AAHHS
AAZKR
ABDBF
ABUWG
ACCFJ
ACXQS
ADBBV
ADKYN
ADRAZ
ADZMN
ADZOD
AEEZP
AENEX
AEQDE
AFKRA
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
D-8
D-9
DIK
EBS
EJD
FYUFA
GODZA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
HZ~
IAO
IHR
KQ8
LK8
M48
M7P
M~E
O9-
OK1
OVD
PIMPY
PQQKQ
PROAC
RPM
TEORI
TUS
UKHRP
WIN
CGR
CUY
CVF
ECM
EIF
ITC
NPM
AAYXX
CITATION
3V.
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c4430-d61cbfb564ea0f0cd9aac0e1b83b4afad949e2afcaec9cc1673f40fd54c6fcf93
IEDL.DBID RPM
ISSN 2045-7634
IngestDate Tue Sep 17 21:08:08 EDT 2024
Sun Sep 29 07:50:33 EDT 2024
Thu Oct 10 18:53:45 EDT 2024
Thu Sep 26 15:30:44 EDT 2024
Sat Sep 28 08:26:59 EDT 2024
Sat Aug 24 00:54:00 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords overall survival
real-world
multiple myeloma
risk stratification
Czech Myeloma Group Registry
monoclonal gammopathies
Language English
License Attribution
2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4430-d61cbfb564ea0f0cd9aac0e1b83b4afad949e2afcaec9cc1673f40fd54c6fcf93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5384-8238
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089168/
PMID 29931775
PQID 2087622077
PQPubID 2032540
PageCount 14
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6089168
proquest_miscellaneous_2058500282
proquest_journals_2087622077
crossref_primary_10_1002_cam4_1620
pubmed_primary_29931775
wiley_primary_10_1002_cam4_1620_CAM41620
PublicationCentury 2000
PublicationDate August 2018
PublicationDateYYYYMMDD 2018-08-01
PublicationDate_xml – month: 08
  year: 2018
  text: August 2018
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Bognor Regis
– name: Hoboken
PublicationTitle Cancer medicine (Malden, MA)
PublicationTitleAlternate Cancer Med
PublicationYear 2018
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
References 2013; 27
2013; 88
2015; 126
2017; 21
2015; 33
2015; 11
2011; 11
1975; 36
2016; 95
2014; 28
2016; 91
2016; 16
2010; 85
2005; 23
2017; 30
2017; 92
2017; 14
2017; 10
2013; 31
2015; 21
2016
2011; 141
1996; 335
2017; 102
2010; 95
2014; 32
2010; 8
e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_21_1
e_1_2_10_22_1
e_1_2_10_20_1
Samaras P (e_1_2_10_15_1) 2011; 141
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_12_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_10_1
e_1_2_10_11_1
e_1_2_10_27_1
e_1_2_10_28_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – volume: 8
  start-page: S28
  issue: Suppl 1
  year: 2010
  end-page: S34
  article-title: In the age of novel therapies, what defines high‐risk multiple myeloma?
  publication-title: J Natl Compr Cancer Netw
– volume: 141
  start-page: w13203
  year: 2011
  article-title: Validation of prognostic factors and survival of patients with multiple myeloma in a real‐life autologous stem cell transplantation setting: a Swiss single centre experience
  publication-title: Swiss Med Wkly
– volume: 92
  start-page: 915
  year: 2017
  end-page: 923
  article-title: Recognition of early mortality in multiple myeloma by a prediction matrix
  publication-title: Am J Hematol
– volume: 14
  start-page: 100
  year: 2017
  end-page: 113
  article-title: Genomic complexity of multiple myeloma and its clinical implications
  publication-title: Nat Rev Clin Oncol
– year: 2016
  article-title: Differences in trial and real‐world populations in the Dutch Castration‐resistant Prostate Cancer Registry
  publication-title: Eur Urol Focus
– volume: 21
  start-page: 91
  year: 2017
  end-page: 101
  article-title: Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation
  publication-title: Expert Opin Ther Targets
– volume: 33
  start-page: 2863
  year: 2015
  end-page: 2869
  article-title: Revised International staging system for multiple myeloma: a report from International Myeloma Working Group
  publication-title: J Clin Oncol
– volume: 31
  start-page: 2806
  year: 2013
  end-page: 2809
  article-title: Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience
  publication-title: J Clin Oncol
– volume: 335
  start-page: 91
  year: 1996
  end-page: 97
  article-title: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome
  publication-title: N Engl J Med
– volume: 102
  start-page: 593
  year: 2017
  end-page: 599
  article-title: Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
  publication-title: Haematologica
– volume: 36
  start-page: 842
  year: 1975
  end-page: 854
  article-title: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
  publication-title: Cancer
– volume: 88
  start-page: 360
  year: 2013
  end-page: 376
  article-title: Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk‐Adapted Therapy (mSMART) consensus guidelines 2013
  publication-title: Mayo Clin Proc
– volume: 30
  start-page: 43
  year: 2017
  end-page: 50
  article-title: Czech Registry of monoclonal gammopathies ‐ technical solution. Data collection and visualisation
  publication-title: Klin Onkol
– volume: 16
  start-page: 511
  year: 2016
  end-page: 518
  article-title: Revised International staging system applied to real world multiple myeloma patients
  publication-title: Clin Lymphoma Myeloma Leuk
– volume: 23
  start-page: 3412
  year: 2005
  end-page: 3420
  article-title: International staging system for multiple myeloma
  publication-title: J Clin Oncol
– volume: 32
  start-page: 2173
  year: 2014
  end-page: 2180
  article-title: Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front‐line autologous stem‐cell transplantation at high risk of early MM progression‐related death
  publication-title: J Clin Oncol
– volume: 11
  start-page: 409
  year: 2011
  end-page: 413
  article-title: Increased serum lactate dehydrongenase should be included among the variables that define very‐high‐risk multiple myeloma
  publication-title: Clin Lymphoma Myeloma Leuk
– volume: 126
  start-page: 4514
  year: 2015
  article-title: Registry of Monoclonal Gammopathies (RMG) in the Czech Republic
  publication-title: Blood
– volume: 85
  start-page: 114
  year: 2010
  end-page: 119
  article-title: High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents
  publication-title: Eur J Haematol
– volume: 95
  start-page: e3521
  year: 2016
  article-title: Prognostic impact of cytogenetic abnormalities in multiple myeloma: a retrospective analysis of 229 patients
  publication-title: Medicine (Baltimore)
– volume: 21
  start-page: 2148
  year: 2015
  end-page: 2156
  article-title: The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma
  publication-title: Clin Cancer Res
– volume: 95
  start-page: 1973
  year: 2010
  end-page: 1976
  article-title: Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
  publication-title: Haematologica
– volume: 28
  start-page: 269
  year: 2014
  end-page: 277
  article-title: IMWG consensus on risk stratification in multiple myeloma
  publication-title: Leukemia
– volume: 10
  start-page: 121
  year: 2017
  article-title: Role of epigenetics‐microRNA axis in drug resistance of multiple myeloma
  publication-title: J Hematol Oncol
– volume: 27
  start-page: 711
  year: 2013
  end-page: 717
  article-title: Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
  publication-title: Leukemia
– volume: 91
  start-page: E473
  year: 2016
  end-page: E477
  article-title: Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma
  publication-title: Am J Hematol
– volume: 11
  start-page: 491
  year: 2015
  end-page: 497
  article-title: Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real‐world practice
  publication-title: J Oncol Pract
– ident: e_1_2_10_13_1
  doi: 10.14735/amko20172S43
– ident: e_1_2_10_6_1
  doi: 10.1186/s13045-017-0492-1
– volume: 141
  start-page: w13203
  year: 2011
  ident: e_1_2_10_15_1
  article-title: Validation of prognostic factors and survival of patients with multiple myeloma in a real‐life autologous stem cell transplantation setting: a Swiss single centre experience
  publication-title: Swiss Med Wkly
  contributor:
    fullname: Samaras P
– ident: e_1_2_10_16_1
  doi: 10.1016/j.clml.2016.06.001
– ident: e_1_2_10_27_1
  doi: 10.1016/j.euf.2016.09.008
– ident: e_1_2_10_28_1
  doi: 10.1056/NEJM199607113350204
– ident: e_1_2_10_14_1
  doi: 10.1182/blood.V126.23.4514.4514
– ident: e_1_2_10_12_1
  doi: 10.1038/leu.2013.247
– ident: e_1_2_10_26_1
  doi: 10.1200/JOP.2015.004929
– ident: e_1_2_10_7_1
  doi: 10.1038/leu.2012.282
– ident: e_1_2_10_2_1
  doi: 10.1200/JCO.2015.61.2267
– ident: e_1_2_10_24_1
  doi: 10.3324/haematol.2010.023697
– ident: e_1_2_10_11_1
  doi: 10.1200/JCO.2005.04.242
– ident: e_1_2_10_4_1
  doi: 10.6004/jnccn.2010.0114
– ident: e_1_2_10_9_1
  doi: 10.1016/j.mayocp.2013.01.019
– ident: e_1_2_10_8_1
  doi: 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
– ident: e_1_2_10_3_1
  doi: 10.1038/nrclinonc.2016.122
– ident: e_1_2_10_20_1
  doi: 10.1200/JCO.2012.46.2598
– ident: e_1_2_10_10_1
  doi: 10.1200/JCO.2013.53.0329
– ident: e_1_2_10_23_1
  doi: 10.1158/1078-0432.CCR-14-2576
– ident: e_1_2_10_21_1
  doi: 10.1097/MD.0000000000003521
– ident: e_1_2_10_25_1
  doi: 10.1002/ajh.24796
– ident: e_1_2_10_5_1
  doi: 10.1080/14728222.2016.1266339
– ident: e_1_2_10_17_1
  doi: 10.3324/haematol.2016.145078
– ident: e_1_2_10_18_1
  doi: 10.1111/j.1600-0609.2010.01466.x
– ident: e_1_2_10_22_1
  doi: 10.1002/ajh.24533
– ident: e_1_2_10_19_1
  doi: 10.1016/j.clml.2011.07.001
SSID ssj0000702671
Score 2.1632004
Snippet This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised...
Abstract This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group ( IMWG ) and...
This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group ( IMWG ) and revised...
SourceID pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 4132
SubjectTerms Adult
Aged
Aged, 80 and over
Cancer Prevention
Clinical medicine
Cytogenetics
Czech Myeloma Group Registry
Czech Republic - epidemiology
Diagnosis
Female
Humans
Male
Middle Aged
monoclonal gammopathies
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - epidemiology
Neoplasm Staging
Original Research
overall survival
Paraproteinemias - diagnosis
Paraproteinemias - epidemiology
Patients
Practice Patterns, Physicians
real‐world
Registries
Retrospective Studies
Risk Assessment
Risk Factors
risk stratification
Survival
Survival Analysis
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVkJcEG8CBQ2IA5eAkzgvLqisWiqkrVBFUW-RPbFbpG5Suu0BfhK_kpnEWVpVcEokW3GSGc988_AMwOuMUXybaRNbZXSsk4pik9U-Jq0zZQUgD5WYFnvF7oH-fJgfBofbKqRVTjJxENRtT-IjZyNd9m2qyvLD6Y9YukZJdDW00LgJGylbCmoGGx-3977sr70szNBpUSZTSSGVviOz1G-TQvp7X1ZE19Dl9STJy-B10D47d-FOgI24NdL5Htxw3X24tQiB8Qfw-xvj6bE9EvYepzRBXP50J_3SoGSQ41gi1wcvHUq0mqUEX_GsZ_7rHE7nJHE6PPUep6ol8lhJJ0U5kIIMG3H-y9ExLsIKgxML993R0D5OZrO46OlEkD5-Mvz_hubHbvUQDna2v85349CGYSRY3BYJWW_zQjujvKK2NoaUS2yVWW28aWtdu9R4Mo5qoqQoM6-Vb3NNhSdfZ49g1vWdewLoW2up1s7nFSMZm1aUleQSzYq6zNlOj-DVRJPmdKy20Yx1ldNGCNcI4SLYnKjVhA23av6yRwQv18O8VST-YTrXX8gcto0GIzOCxyNx16uwVmYkVeYRlFfIvp4gZbivjnTfj4dy3IWqGGNXEbwZGOTfL97MtxZabp7-_wuewW2GZdWYZrgJs_OzC_ecoc-5fRH4-w-Bswp7
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access(OpenAccess)
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1baxUxEB5KBfFFvLtaZRQffNm6l-xNECkHaxGOD-KRvi3JbGKFc3b1tAXrT_JXOpPdHHqo-rQLyV6_SfJNMvkG4EXOLL7LlY5NolWs0ppinTcuJqXyxAhB9kpM84_l0UJ9OC6OdyDk2Jx-4OlfXTvJJ7VYL_d__rh4yw3-zSQg-or0Su2nZcae-7VMsYMuEXwTy_cdciVpltKgK3T5iu3R6ArFvBopeZnB-iHo8BbcnLgjHoxg34Yd29-B6_Npdfwu_P7CpHrMkYSDwxAriKsLuxxWGiWMHEedXDdN1aEsWXNXwUdcD2yEvcWwWRLDDqrXGKRL5LYSU4qyKwWZO-Lsl6UTnE9P8DNZ-Ml-9TnkpDb3GQMthe7je8027zMg29N7sDh893l2FE-5GEbU4q5MyThTlMrqxCXUNVpTYlNT50Zpp7tGNTbTjrSlhigtq9ypxHWFotKRa_L7sNsPvX0I6DpjqFHWFTXTGZPVlFdkU8WjdVWwsx7B84BJ-32U3GhHceWsFeBaAS6CvYBWG4ymzURfL8uSqorg2aaY24ssgujeDudShx0k72lG8GAEd_MUHpqZTlVFBNUW7JsKosW9XdJ_O_Ga3GVSM9GuI3jpDeTfL97ODuZKTh79_wseww3mZvUYa7gHu2frc_uE-c-Zeeqt-w9qqwrK
  priority: 102
  providerName: Scholars Portal
– databaseName: Wiley-Blackwell Open Access Titles(OpenAccess)
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9VAEB5KC-KLWK_RKqP44EvsZrO56VM5WItwRMRK38LuZtcKPYn0tA_6k_orO7ObRA9F8CmBnVxgZna-mZ39FuBVTii-y5VOjdAqVVltU503PrVK5cIwQA5MTMtP5dGx-nhSnGzBu2kvTOSHmAtu7BlhvmYH12a9_4c01OqVepOVkvL1HWaMYeJ8qT7PBRayZVmGhIsZ11PyIzUxCwm5Pz-9GY9ugMybvZJ_Y9gQhA7vwp0RPeJBVPcubLn-Htxajuvj9-HqG8HqeEoSDh6nbkFc_XJnw0ojN5JjZMr1Y7EOedGaJgu64vlAZtg7nLZL4rSH6i1O5CX8Wu4qRd6XgoQecfHb2VNcjl8ItSz84r6HU-RYmmaNwZ4x4McPmqw-nIHs1g_g-PD918VROp7GEPWWdmVmjTdFqZwWXtiu0doKl5k6N0p73TWqcVJ7q51trM3KKvdK-K5QtvTWN_lD2O6H3j0G9J0xtlHOFzUBGiNrm1fWZYridVVQup7Ay0kn7c9IutFGemXZsuJaVlwCe5O22tHv1q1khj0pRVUl8GIeJo_hZRDdu-GSZShFCrlmAo-icuevUHAmQFUVCVQbap8FmI17c6T_cRpYuUtRE9SuE3gdDOTfP94uDpaKb578v-hTuE1IrY6dh3uwfXF-6Z4RGrowz4PVXwOw_ArT
  priority: 102
  providerName: Wiley-Blackwell
Title Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcam4.1620
https://www.ncbi.nlm.nih.gov/pubmed/29931775
https://www.proquest.com/docview/2087622077
https://search.proquest.com/docview/2058500282
https://pubmed.ncbi.nlm.nih.gov/PMC6089168
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6yKZReSt91my5q6aEX78q2_OotXfKg4LCEpuzNSGMpCaztkMeh_Un9lR3J1rIh9NKLbLCwBDOSPknffAPwOSEU3yRChopLEYqowFAmpQlRiIQrC5CdElN1kh2fie-rdLUDqY-FcaR9VJezbt3OussLx628anHueWLzZbXIeEGopphPYEIOurVFd9NvbpMqRV5FiMdzlK2YRVlss77R7EsrpmUVbi9DD7DlQ4rkNnR1a8_hM3g6gka2P3TuOezo7gU8rsZr8Zfw5yeh6SE5EusN8yRB1v7S676VzPLH2SCQa8YzOmbvqmmOoCe77sn7Os18lCTzoVNfmdcssb-1ZFJmw1EYgUa2-K3xglVjC-4Ii53qc5c8ztamyaLHtcX57EiSs7vUx_rmFZwdHvxYHIdjEobBXGGTRaiMSjOhJTccm1JK5DpSRaKENLIpRaljaVBqLBGjLE-M4KZJBWYGTZm8ht2u7_RbYKZRCkuhTVoQjlFxgUmOOhK0TOcp7dID-ORtUl8NWhv1oKoc19aGtbVhAHveWvU43G7q2ArrxTHP8wA-bj7TQLG3H7LT_Z2tQzsjt8UM4M1g3E0r3isCyO-ZfVPBinDf_0K-6cS4R18M4ItzkH93vF7sV8K-vPvvRt7DE8JrxcA_3IPd2-s7_YEw0a2awiQWSyrzVT6FR98OTpanU3e-QOXRKqKyEsXUjZS_lrkYRQ
link.rule.ids 230,315,730,783,787,867,888,2228,11574,12068,21400,24330,27936,27937,31731,31732,33756,33757,43322,43817,46064,46488,50826,50935,53804,53806,74079,74636
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BkYAL4k2ggEEcuITm4cQJF1StKAs0PaAW7S2yJzZF6ial2x7gJ_ErmXGcpVUFp0SyFSeZ8czn8fgbgFc5ofgulzo2iZaxTCuMdV67GKXME8MA2TMxNXvl_EB-WhSLEHBbhbTKySZ6Q90NyDFyWqTzvM0Spd4d_4i5ahTvroYSGlfhGvNwcQUDtVDrGAupc1aqdCIUSrIt1Ev5Ji25uvd5N3QJW15OkTwPXb3v2bkNtwJoFNujlO_AFdvfhetN2Ba_B7-_EpoeiyOJwYkpSVAsf9qjYakF54-LkSDXhRid4L1qshF0FScDaV9vxXRKUkxHp96KibOEH8vJpIKPowgCjWL2y-KhaMIIPoQlvthvvngc9yZjMeAR43zxQdPf86WP7eo-HOy835_N41CEYRRX3JUpGmeKUlqduAS7WmtMbGqq3EjtdFfL2mbaobZYI6alyp1MXFdILB26On8AG_3Q20cgXGcM1tK6oiIcY7IKc4U2leSmVUGr9AheTjJpj0eujXZkVc5aFlzLgotgc5JWG6bbqv2rHBG8WDfTROHdD93b4Yz70MrILzEjeDgKdz0K-WTCUaqIQF0Q-7oDk3BfbOm_H3oy7jKpCGFXEbz2CvLvF29n243km8f__4LncGO-3-y2ux_3Pj-BmwTQqjHhcBM2Tk_O7FMCQafmmdf0P8V4DAY
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7RIlW9IN4EChjEgUtoHk6ccEHVwrYFtkKIor1F9sSmSN2kdNsD_CR-JTOOs7Sq4JRItuIkM5755uEZgBc5ofg2lzo2iZaxTCuMdV67GKXME8MA2Vdimh2Ue4fy_byYh_ynZUirHGWiF9Rtj-wjJyOd922WKLXtQlrEp7fTNyc_Yu4gxZHW0E5jDa4rslKYw9VcrfwtxNpZqdKxuFCSbaNeyFdpyZ2-L6qkKzjzarrkRRjr9dD0JtwIAFLsDBS_Bddsdxs2ZiFEfgd-fyVkPTRKEr0TY8KgWPy0x_1CC84lF0OxXBf8dYLj1iQv6CpOe-LEzorxxKQYj1G9FmP9En4sJ5YKPpoiCECKyS-LR2IWVvDuLPHZfvON5Hg2CY4ejxnzi11Nf8-3QbbLu3A4ffdlsheHhgwD6eK2TNE4U5TS6sQl2NZaY2JTU-VGaqfbWtY20w61xRoxLVXuZOLaQmLp0NX5PVjv-s4-AOFaY7CW1hUVYRqTVZgrtKkkla0KstgjeD7SpDkZ6m40Q4XlrGHCNUy4CLZGajVh6y2bv4wSwbPVMG0ajoTozvbnPIesJG9uRnB_IO5qFdLPhKlUEYG6RPbVBC7IfXmk-37kC3OXSUVou4rgpWeQf794M9mZSb55-P8veAobxOTNx_2DD49gk7BaNeQebsH62em5fUx46Mw88Yz-BxFBEEQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Validation+of+multiple+myeloma+risk+stratification+indices+in+routine+clinical+practice%3A+Analysis+of+data+from+the+Czech+Myeloma+Group+Registry+of+Monoclonal+Gammopathies&rft.jtitle=Cancer+medicine+%28Malden%2C+MA%29&rft.au=Radocha%2C+Jakub&rft.au=Maisnar%2C+Vladim%C3%ADr&rft.au=Pour%2C+Lud%C4%9Bk&rft.au=%C5%A0pi%C4%8Dka%2C+Ivan&rft.date=2018-08-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.eissn=2045-7634&rft.volume=7&rft.issue=8&rft.spage=4132&rft.epage=4145&rft_id=info:doi/10.1002%2Fcam4.1620&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-7634&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-7634&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-7634&client=summon